Transgene Biotek blames Nirmal Kotecha in GDR case

Image
Press Trust of India Mumbai
Last Updated : Dec 15 2014 | 5:55 PM IST
Slapped with Sebi's restraint order in a case related to raising of funds through Global Depository Receipts, Transgene Biotek has put the blame on Nirmal Kotecha for doing "forgery and fraud" on the firm.
While, the pharma company is filing an appeal before the Securities Appellate Tribunal against Sebi interim order, it is also in the process of filing complaints against Kotecha, who was also involved in a major securities market manipulation at Pyramid Saimira Theatre few years ago.
In a BSE filing today, Transgene Biotek also said that the ED (Enforcement Directorate) "is seized of the matter as informed to Sebi, on the...Forgery and fraud".
A preliminary probe by Securities and Exchange Board of India (Sebi) found that Transgene Biotek had transferred USD 29.92 million, out of total GDR proceeds of USD 40.5 million, through a subsidiary "for undisclosed and ulterior purposes under the garb of consideration for technology transfer and for other reasons".
After raising of funds, the money was first kept in a Switzerland-based bank and some parts were later transferred to other entities in Hong Kong and Canada, among others, including to a subsidiary.
Accordingly, pending detailed probe in the matter, Sebi had through a interim order last month directed Transgene "not to issue equity shares or any other instrument convertible into equity shares or any other security till further orders".
It has also barred Transgene chairman and managing director K Koteswara Rao and five others from the dealing in the securities market, till further directions.
In the filing, Transgene Biotek has clarified that the company was "enticed" by Kotecha for raising funds for various operations such as acquisition of technologies and arranging clinical and pre-clinical studies on its molecules.
"Nirmal Kotecha and his aide Kishore Tapadia convinced the management of funding with GDR proceeds and structured the whole process in a manner essentially ensuring that it would get the much desired funds in a legal transparent manner," Transgene Biotek said.
Further, the company said that the funds deposited in Switzerland's Investec Bank were siphoned away in the names various entities and banks statements were provided by Kishore Tapadia "camouflaging to show normal balances".
Transgene Biotek has claimed that the funds were transferred fraudulently on basis of forged letter to the banks under the signature of the company's CMD.
"Nirmal Kotecha, we understand admitted to ED on the said siphoning of funds," the company added.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 15 2014 | 5:55 PM IST

Next Story